Background. Human papillomavirus (HPV) vaccination was introduced into the routine
immunization schedule in the United States in late 2006 for females aged 11 or 12 years …

Background Human papillomavirus (HPV) vaccine was recommended in 2006 for routine
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was …

Abstract The 2003–2006 National Health and Nutrition Examination Surveys were used to
assess human papillomavirus (HPV) types 6, 11, 16, and 18 DNA detection from females …

BACKGROUND: Human papillomavirus (HPV) vaccination is recommended to protect
against HPV-related diseases. OBJECTIVE: To estimate HPV vaccine coverage and assess …

Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …

BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine
demonstrate high efficacy, but surveillance studies are essential to examine the long-term …

Background To assess the demographic and attitudinal factors associated with HPV vaccine
initiation and completion among 18–26 year old women in Utah. Method Between January …

BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …

We analyzed human papillomavirus (HPV) prevalences during prevaccination and
postvaccination periods to consider possible changes in nonvaccine HPV genotypes after …

Purpose: To examine correlates of HPV vaccination uptake in a nationally representative
sample of 18–26-year-old adults. Methods: Young adults aged 18–26 years were identified …